קנדה - אנגלית - Health Canada

apotex inc - ropinirole (ropinirole hydrochloride) - tablet - 5.0mg - ropinirole (ropinirole hydrochloride) 5.0mg - nonergot-derivative dopamine receptor agonists

קנדה - אנגלית - Health Canada

jamp pharma corporation - ropinirole (ropinirole hydrochloride) - tablet - 0.25mg - ropinirole (ropinirole hydrochloride) 0.25mg - nonergot-derivative dopamine receptor agonists

קנדה - אנגלית - Health Canada

jamp pharma corporation - ropinirole (ropinirole hydrochloride) - tablet - 1.0mg - ropinirole (ropinirole hydrochloride) 1.0mg - nonergot-derivative dopamine receptor agonists

קנדה - אנגלית - Health Canada

jamp pharma corporation - ropinirole (ropinirole hydrochloride) - tablet - 2.0mg - ropinirole (ropinirole hydrochloride) 2.0mg - nonergot-derivative dopamine receptor agonists

קנדה - אנגלית - Health Canada

jamp pharma corporation - ropinirole (ropinirole hydrochloride) - tablet - 5.0mg - ropinirole (ropinirole hydrochloride) 5.0mg - nonergot-derivative dopamine receptor agonists

ארצות הברית - אנגלית - NLM (National Library of Medicine)

apotex corp. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - ropinirole tablets are indicated for the treatment of parkinson’s disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole hydrochloride is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole hydrochloride in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these dr

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 0.285mg equivalent to to 0.25 mg ropinirole - film coated tablet - 0.25 mg - active: ropinirole hydrochloride 0.285mg equivalent to to 0.25 mg ropinirole excipient: citric acid hyprolose hypromellose lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 0.57mg equivalent to to 0.5 mg ropinirole - film coated tablet - 0.5 mg - active: ropinirole hydrochloride 0.57mg equivalent to to 0.5 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 1.14mg equivalent to to 1 mg ropinirole - film coated tablet - 1 mg - active: ropinirole hydrochloride 1.14mg equivalent to to 1 mg ropinirole excipient: citric acid hyprolose hypromellose indigo carmine aluminium lake iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole - film coated tablet - 2 mg - active: ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide red lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.